Cargando…
Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY
Autores principales: | Joergensen, Kristin K., Syversen, Silje W, Jyssum, ingrid, Tveter, Anne Therese, Tran, Trung T., Sexton, Joe, Provan, Sella A., Mjaaland, Siri, Warren, David J., Kvien, Tore K., Gr⊘deland, Gunnveig, Nissen-Meyer, Lise Sofie H., Ricanek, Petr, Chopra, Adity, Anderson, Ane M., Kro, Grete B., Munthe, Ludvig A., Haavardsholm, Espen A., Vaage, John T.T., Lund-Johansen, Fridtjof, Jahnsen, Jorgen, Goll, Guro L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AGA Institute. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212477/ http://dx.doi.org/10.1016/S0016-5085(22)60679-6 |
Ejemplares similares
-
Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
por: Syversen, Silje W., et al.
Publicado: (2022) -
The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022) -
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
por: Syversen, Silje Watterdal, et al.
Publicado: (2022) -
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
por: Bjørlykke, Kristin H, et al.
Publicado: (2023) -
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
por: Jyssum, Ingrid, et al.
Publicado: (2022)